SPONSOR
Yongyi Zeng
Total Trials
2
Recruiting
2
Phases
Phase 2, EARLY_Phase 1
Yongyi Zeng is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma.
The trial portfolio spans Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Yongyi Zeng
How many clinical trials has Yongyi Zeng sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Yongyi Zeng, of which 2 are actively recruiting participants. These trials cover conditions including Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Yongyi Zeng research focus on?
Yongyi Zeng clinical trials span Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma. The research pipeline includes Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Yongyi Zeng clinical trial?
To participate in a Yongyi Zeng trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Yongyi Zeng trials with current recruitment status updated daily.
Clinical Trials by Yongyi Zeng
NCT06349317 Phase 2
Recruiting
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Hepatocellular Carcinoma
NCT06406816 EARLY_Phase 1
Recruiting
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
Intrahepatic Cholangiocarcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology